Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2010, Issue 1, Pages 481-488
Publisher
American Society of Hematology
Online
2011-01-17
DOI
10.1182/asheducation-2010.1.481
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploiting synthetic lethal interactions for targeted cancer therapy
- (2011) H. Christian Reinhardt et al. CELL CYCLE
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
- (2010) P. Dreger et al. BLOOD
- Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
- (2010) D. Oscier et al. HAEMATOLOGICA
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
- (2009) P. Abrisqueta et al. BLOOD
- Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
- (2009) J. Malcikova et al. BLOOD
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
- (2009) T. Zenz et al. BLOOD
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
- (2009) C. S. Tam et al. BLOOD
- How I treat CLL up front
- (2009) J. G. Gribben BLOOD
- Treatment of fludarabine-refractory chronic lymphocytic leukemia
- (2009) Apostolia-Maria Tsimberidou et al. CANCER
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Prognostic implications of anemia in older adults
- (2009) K. V. Patel et al. HAEMATOLOGICA
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
- (2009) Francesc Bosch et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
- (2009) S Böttcher et al. LEUKEMIA
- Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency
- (2008) F. Guillem et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- miR-34a as part of the resistance network in chronic lymphocytic leukemia
- (2008) T. Zenz et al. BLOOD
- The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
- (2008) F Dicker et al. LEUKEMIA
- A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
- (2008) O G Best et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started